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Recommended by Ryichi Kikkawa
The prescription of anaerobic exercise has recently been advocated for the management of diabetes; however exercise-induced
signaling in diabetic muscle remains largely unexplored. Evidence from exercise studies in nondiabetics suggests that the
extracellular-signal-regulated kinases (Erk1/2), p38, and c-JUN NH2-terminal kinase (Jnk) mitogen-activated protein kinases
(MAPKs) are important regulators of muscle adaptation. Here, we compare the basal and the in situ contraction-induced
phosphorylation of Erk1/2- p38- and Jnk-MAPK and their downstream targets (p90rsk and MAPKAP-K2) in the plantaris and
soleus muscles of normal and obese (fa/fa) Zucker rats. Compared to lean animals, the time course and magnitude of Erk1/2,
p90rsk and p38 phosphorylation to a single bout of contractile stimuli were greater in the plantaris of obese animals. Jnk
phosphorylation in response to contractile stimuli was muscle-type dependent with greater increases in the plantaris than the
soleus. These results suggest that diabetes alters intramuscular signaling processes in response to a contractile stimulus.
Copyright © 2008 A. Katta et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Exercise has long been recognized to have important health
benefits for people with type II diabetes. The molecular
events underlying exercise-induced adaptations in diabetic
muscle remain largely undefined. It is thought that beneficial
effects of exercise on structural and functional adaptations
of muscle are mediated through the activation of vari-
ous signaling molecules, which activate signaling cascades
involved in regulating changes in gene expression. Similar
to that seen with aerobic exercise modalities [1–3], recent
data has suggested that anaerobic exercise may also be
beneficial in the treatment of diabetes [4–11]. For example,
progressive resistance training has been found to improve
glycemic control, increase skeletal muscle size and strength,
and positively change body composition by increasing lean
body mass and decreasing visceral and total body fat [12–
15]. Whether diabetes is characterized by differences in
how muscle responds to resistance training is not well
understood.
Although not fully delineated, it has been postulated
that the mitogen activated protein kinase (MAPK) signaling
cascade may be particularly important in mediating the
effects of altered contractile activity. Indeed, muscle contrac-
tion and load-induced muscle hypertrophy in humans and
rodents have been found to be associated with the activation
of the extracellular signal-regulated kinases 1/2 (Erk1/2),
p38, and c-Jun NH2-terminal kinase (Jnk) MAPK proteins
[16–20]. Several downstream substrates of MAPK signaling
have also been identified, including the Erk1/2-dependent
protein MAPK-activated proteinkinase-1 (MAPKAP-K1),
also called p90 ribosomal S6kinase (p90RSK) [21] and the
p38-dependent protein MAPK-activated protein kinase-2
(MAPKAP-K2) [22, 23]. It is thought that the phosphory-
lation (activation) of MAPK proteins and their substrates
is important in regulating such diverse processes as gene
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expression, glucose uptake, cell replication, and protein
synthesis [16, 24, 25]. To our knowledge, the effect of
diabetes on contraction-induced MAPK signalingin muscle
has not been investigated.
The purpose of this study was to examine whether
diabetes alters MAPK signaling after an acute bout of con-
tractile activity. We hypothesized that contraction induced
MAPK signaling would differ between normal and diabetic
muscles. To test this hypothesis, the phosphorylation status
of Erk1/2-, p38-, and Jnk-MAPK and their downstream
kinases were analyzed in the plantaris and soleus muscles of
the normal and diabetic rats immediately after and during
the recovery phase of an acute bout of high-frequency
electrical stimulation. Taken together, our data suggests that
diabetes alters contraction-induced MAPK phosphorylation
in skeletal muscle.
2. MATERIALS AND METHODS
2.1. Animal care
Young (10 weeks, n = 12) male lean normal Zucker (LNZ)
and young (10 weeks, n = 12) male obese syndrome-X
Zucker (OSXZ) rats were obtained from the Charles River
Laboratories. Rats were housed to a cage in an AAALAC
approved vivarium. Housing conditions consisted of a 12H:
12H dark-light cycle and temperature was maintained at
22◦ ± 2◦c. Animals were provided food and water ad
libitum and allowed to recover from shipment for at least
two weeks before experimentation. During this time, the
animals were carefully observed and weighed weekly to
ensure none exhibited signs of failure to thrive, such as
precipitous weight loss, disinterest in the environment, or
unexpected gait alterations. All procedures were performed
as outlined in the Guide for the Care and Use of Laboratory
Animals as approved by the Council of the American Phys-
iological Society and the institutional Animal Use Review
Board.
2.2. Materials
Anti-Erk1/2 (#9102), phospho-Erk1/2Thr202/Tyr204 (#9106),
p38(#9212), phospho-p38Thr180/Tyr182 (#9216), SAPK/Jnk
(#9252), phospho-SAPK/JnkThr183/Tyr185 (#9251), p90RSK
(#9334), phospho-p90RSK Ser380(#9335), MAPKAP-K2
(#3042), phospho-MAPKAP-K2Thr334 (#3007), Mouse
IgG, and Rabbit IgG antibodies were purchased from Cell
Signaling Technology (Beverly, Mass, USA). Enhanced
chemiluminescence (ECL) western blotting detection
reagent was from Amersham Biosciences (Piscataway, NJ,
USA). Restore western blot stripping buffer was obtained
from Pierce (Rockford, Ill, USA), and 3T3 cell lysates
were from Santa Cruz Biotechnology (Santa Cruz, Calif,
USA). Antirabbit and antimouse fluorescein antibodies and
VectaSheild Hardset Mounting Medium with DAPI was
purchased from Vector Laboratories (Burlingame, Calif,
USA). All other chemicals were purchased from Sigma (St.
Louis, Mo, USA) or Fisher Scientific (Hanover, Ill, USA).
2.3. Contractile stimulation of skeletal muscles
The high-frequency electrical stimulation (HFES) model
has been previously described [26] and was chosen on the
basis of its efficacy in stimulating protein translation and
muscle hypertrophy in vivo [27]. By directly stimulating the
motor nerve, this model elicits a maximal contraction that
when repeated over time produces a muscle adaptation that
closely mimics that seen in humans following a program
of resistance training. HFES loading of the rat hindlimb
was performed using a voltage of 5–7 V (1-millisecond
pulses, 100 Hz) as described previously [27]. These condi-
tions have been shown to produce a maximal contraction.
Muscle contractions lasted 3 seconds and were followed by
a 10-second rest. Ten sets of 6 repetitions were performed
with each set being separated by a 50-second rest period. This
protocol results in concentric (shortening) contraction of
the plantaris and soleus. The fast-twitch plantaris (PLA) and
slow-twitch soleus (Sol) muscles were chosen on the basis
of previous studies demonstrating that HFES induces MAPK
phosphorylation in these muscles [17, 28–30]. Animals were
killed by drug overdose at baseline, immediately following,
1hour or 3 hours (n = 6 normal, n = 6 diabetic for 0, 1,
and 3 hours) after HFES. Once excised, muscles were blotted
dry, trimmed of visible fat and tendon projections, weighed,
immediately frozen in liquid nitrogen, and stored at −80◦C.
2.4. Preparation of protein isolates
and immunoblotting
Muscles were pulverized in liquid nitrogen using a mortar
and pestle until a fine powder was obtained. After washing
with ice cold PBS, pellets were lysed on ice in for 15
minutes in T-PER (2 mL/1 g tissue weight) (Pierce, Rockford,
Ill, USA) and centrifuged for 10 minutes at 2000 X g to
pellet particulate matter. This process was repeated twice
and the supernants combined for protein concentration
determination using the Bradford method (Pierce, Rockford,
Ill, USA). Samples were diluted to a concentration of 3 μg/μL
in SDS loading buffer, boiled for 5 minutes, and 60 μg of
protein were separated using 10% SDS-PAGE gels. Transfer
of protein onto nitrocellulose membranes, verification of
transfer, and determination of equal loading between lanes
and membranes was determined as outlined previously [31].
Protein immunodetection was performed as outlined by the
antibody manufacturer while immunoreactive bands were
visualized with ECL (Amersham Biosciences, NJ, USA).
Exposure time was adjusted to keep the integrated optical
densities within a linear and nonsaturated range. Band signal
intensity was normalized to β-actin by densitometry using a
flatbed scanner (Epson Perfection 3200 PHOTO) and imag-
ing software (AlphaEaseFC). Molecular weight markers (Cell
Signaling) were used as molecular mass standards, and NIH
3T3 cell lysates were included as positive controls. To allow
direct comparisons to be made between the concentration
levels of different signaling molecules, immunoblots were
stripped and re-probed with Restore western blot stripping
buffer as detailed by the manufacturer (Pierce, Rockford, Ill,
USA).
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Table 1: Body weight and muscle mass of lean and obese (fa/fa) Zucker rats. An asterisk (∗) indicates significant differences (P < .05) from
the lean Zucker value.
Lean Zucker Obese Zucker
Body mass, g 328 ± 12.2 597 ± 21.7∗
PLA mass, mg 373 ± .009 244 ± .007∗
PLA mass/Body Wt (mg/g) 1.14 ± .43 0.41 ± .12∗
SOL mass, mg 143 ± .005 146 ± .008
SOL mass/Body Wt (mg/g) 0.44 ± .13 0.24 ± .12∗
2.5. Statistical analysis
Results are presented as mean ± SEM. Data were analyzed
by using the Sigma Stat 3.0 statistical program. Effects of
exercise on type II diabetes mellitus in the presence of
metabolic syndrome were analyzed using a two-way ANOVA
followed by the Student-Newman-Keuls post hoc testing
when appropriate. A P value < .05 was considered to be
statistically significant.
3. RESULTS
Average body mass of obese Zucker rats was ∼82% higher
than lean counterparts (P < .05) (see Table 1). Plantaris and
solues muscle mass in obese Zuckers, as a percentage of body
weight, was only ∼34% and ∼58%, respectively, of muscle
mass in lean Zuckers (P < .05) (see Table 1).
3.1. MAPK protein levels and phosphorylation status
are altered in the diabetic soleus and plantaris
Immunoblotting analysis of proteins normalized to β-actin
indicated that there were no significant differences in total
p38 MAPK content in plantaris and solues in the OSXZ
compared to the LNZ (P < .05) (see Figure 1). Plantaris
Erk1/2 (p44/p42) content was not significantly different
between the groups, while Erk1/2(p44/p42) content in the
OSXZ soleus was 17.0±4.8% and 20.3±6.9% lower (P < .05)
than that observed in their lean counterparts (see Figure 1).
Jnk1 levels were 46.1 ± 10.2% higher in OSXZ plantaris
and 22.2 ± 7.2% higher in the OSXZ soleus, compared
to LNZ (P < .05) (see Figure 1). Jnk2 expression was
29.0 ± 9.34% higher in OSXZ plantaris as compared to lean
counterparts (P < .05), with no significant difference in the
OSXZ soleus muscle (see Figure 1). There was no detectable
expression of Jnk3 in the plantaris, while Jnk3 content did
not differ between LNZ and OSXZ solei. There were no
significant differences between OSXZ and LNZ in p90RSK,
or MAPKAP-K2 protein levels for either the plantaris or
soleus (data not shown).
Basal levels of phosphorylated forms of MAPK proteins
were measured to determine if diabetes altered MAPK
activation. Immunoblot analysis using phospho-specific
antibodies indicated that the basal level of phospho-Erk1/2
was 41.2 ± 13.3% and 45.1 ± 13.4% lower (P < .05),
respectively, in OSXZ soleus compared to LNZ, with no
significant difference in the plantaris (see Figure 2). The basal
level of p38 phosphorylation was unchanged in the plantaris
and was 24.9 ± 8.7% lower in the OSXZ versus the LNZ
soleus (P < .05) (see Figure 3). There was no difference
in the basal expression of any of the phosphorylated Jnk
isoforms between LNZ and OSXZ muscles (see Figure 4).
In the plantaris, the basal phosphorylation level of p90s6k
was 128.3± 19.28% higher OSXZ compared to the LNZ rats
(P < .05) while the basal phosphorylation of MAPKAP-K2
was unchanged (see Figure 5).
3.2. MAPK phosphorylation in response to
contractile stimulus is altered by diabetes
Phosphorylation of p38, Erk1/2, and Jnk-MAPK was deter-
mined at 0, 1, and 3 hours after a bout of HFES for
comparison with control values. In the case of each molecule
examined, significant differences existed between lean and
obese Zucker rat models. Differences also were present
between the predominately fast twitch plantaris and slow
twitch soleus (see Figures 2–4). LNZ plantaris muscles
showed no differences in p38 phosphorylation status post
exercise. Conversely, the OSXZ plantaris exhibited a 38.5 ±
33.8% increase in phosphorylation from baseline at 3-hours
post exercise (P < .05) (see Figure 3). The LNZ soleus had a
33.5± 9.7% and 27.2± 8.0% decrease in phosphorylation of
p38 at 1 and 3 hours post exercise, respectively, while OSXZ
soleus muscles showed an increase of 18.8±10.7% at 3 hours
post exercise from the baseline (P < .05) (see Figure 3).
Both Erk1/2 MAP kinases showed significant increases
in phosphorylation levels from baseline in response to the
contractile stimulus. In the plantaris muscle, LNZ animals
had an increase in phosphorylation of Erk1 (p44) of 106.1±
13.8%, 59.8± 10.9%, and 215.9± 29.5 % at 0, 1, and 3hours,
respectively. OSXZ animals showed an increase of 244.3 ±
24.7%, 239.3 ± 13.9%, and 200.3 ± 28.7% at 0, 1, and 3
hours, respectively, (P < .05) (see Figure 2). The slow twitch
soleus muscle of LNZ had an increase in the phosphorylation
level of p44 by 51.3± 9.3%, 90.3± 14.9%, and 36.8± 13.7%
from baseline at 0, 1, and 3 hours, respectively, (P < .05).
The soleus muscles of OSXZ animals responded differently
with increases in p44 phosphorylation of 124.7± 19.7% and
78.5 ± 25.9% at 0 and 3 hours, respectively, (P < .05) (see
Figure 2). In LNZ animals, the plantaris exhibited increases
of Erk2 (p-42) phosphorylation of 368.5 ± 16.6%, 244.2 ±
29.8%, and 364.1±22.3%, while contraction in OSXZ elicited
increases in p-42 phosphorylation of 582.7± 55.2%, 679.0±
48.2%, and 716.6 ± 9.2% at 0, 1, and 3 hours, respectively,
(P < .05) (see Figure 2). LNZ soleus muscles increased
p42 phosphorylation by 24.8 ± 55.2%, 43.3 ± 55.2%, and
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Figure 1: Type 2 diabetes is associated with alterations in skeletal muscle MAPK proteins. Plantaris and soleus muscles from LNZ and obese
(fa/fa) Zuckers (OSXZ) were analyzed by Western blot analysis for diabetes-related changes in total Erk1/2-, p38 MAPK, and Jnk protein
expression. Protein quantification was normalization to the abundance of β-actin. Results are expressed as a percent of the normal, LNZ
value. An asterisk (∗) indicates significant differences (P < .05) from the lean Zucker value.
15.5±55.2% above baseline at 0, 1, and 3 hours, respectively,
(P < .05). This response appeared greater in OSXZ
solei as soleus contraction in these animals increased the
phosphorylation of p42 by 120.9± 55.2%, 30.5± 55.2%, and
122.0±55.2% at 0, 1, and 3 hours, respectively, (P < .05) (see
Figure 2).
Similar to ERK1/2 and p38, muscle contraction also
increased the phosphorylation of Jnk isoforms. In the LNZ
plantaris, Jnk1 phosphorylation increased 115.2 ± 31.9%,
140.0 ± 27.9%, and 105.4 ± 34.5%, and Jnk2 by 354.2 ±
140.3%, 472.8 ± 49.7%, and 153.0 ± 70.0% from baseline at
0, 1, and 3 hours, respectively, (P < .05). In obese animals,
Jnk1 phosphorylation with contraction was increased by
65.2 ± 35.3%, 92.7 ± 36.5%, and 52.7 ± 27.1%, and Jnk2
by 300.4 ± 97.8%, 417.8 ± 72.2% and 174.5 ± 58.2% from
baseline at 0, 1, and 3 hours, respectively, (P < .05) (see
Figure 4). In LNZ soleus muscles, HFES did not change
the phosphorylation level of Jnk1 and Jnk2 from that seen
in control animals, however the phosphorylation level of
Jnk3 increased 36.7 ± 7.2% from baseline immediately after
exercise (P < .05). HFES did not alter Jnk1, Jnk2, or Jnk3
phosphorylation in the OSXZ soleus (see Figure 4).
To determine whether differences in MAPK signaling
with type II diabetes were associated with changes in the reg-
ulation of potential downstream MAPK targets, we examined
the regulation of p90RSK and MAPKKAP-K2. Contraction
induced significant increases in phosphorylation levels of
p90s6k (downstream target of Erk1/2) from baseline in the
plantaris muscles of both normal and diabetic animals. In
the LNZ animals, HFES increased the phosphorylation level
of p90s6k by 382.2±22.3%, 304.4±17.4%, and 387.8±24.7%
from baseline at 0, 1, and 3 hours, respectively. In a similar
fashion, plantaris muscles from obese animals demonstrated
increases in phosphorylation of p90s6k of 134.0 ± 7.6%,
135.5 ± 6.7%, and 144.5 ± 9.5% from baseline at 0, 1, and
3 hours, respectively (P < .05) (see Figure 5). Conversely, the
plantaris muscles of LNZ had a decrease in phosphorylation
level of MAPKAP-K2 (downstream target of p38) by 14.5 ±
4.6%, 14.3 ± 4.1%, and 8.1 ± 6.0% from baseline at 0,
1, and 3 hours, respectively. Plantaris muscles of OSXZ
animals responded in a similar way and exhibited decreases
in MAPKAP-K2 phosphorylation of 27.5±4.2%, 31.1±4.6%,
and 40.0 ± 5.6% at 0, 1, and 3 hours, respectively, (P <
.05) (see Figure 5). No evidence of p90RSK or MAPKAP-K2
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Figure 2: Contraction-induced Erk1/2-MAPK phosphorylation is altered with type II diabetes. Plantaris and soleus muscles from lean
(LNZ) and obese Zucker (OSXZ) rats were obtained immediately after, 1 and 3 hours after a bout of HFES. Alterations in Erk1 (a),(b)
and Erk2 (c),(d)-MAPK phosphorylation with exercise were determined by immunoblotting. An asterisk (∗) indicates significant difference
(P < .05) from the control within animal model, and a cross (†) indicates significant difference (P < .05) at corresponding time points across
animal models.
phosphorylation in any of the soleus muscles examined (data
not shown).
4. DISCUSSION
The obese Zucker (fa/fa) rat is an animal model of severe
skeletal muscle insulin resistance that is also characterized
bymarked hyperinsulinemia and glucose intolerance, dys-
lipidemia, and central adiposity and therefore is a suitable
animal model of the insulin resistance syndrome [32]. It
is thought that the mechanisms underlying the progression
of insulin resistance in these animals closely mimic that
seen in human type II diabetes [33]. The objective of this
study was to examine how type II diabetes affects how
skeletal muscle responds to a contractile stimulus. Our
findings suggest that diabetes is associated with alterations
in how muscle contraction regulates MAPK signaling and
are consistent with the notion that diabetes may affect the
regulation of these proteins differently depending upon fiber
type.
5. TYPE II DIABETES ASSOCIATED
ALTERATION IN MAPK PROTEIN CONTENT AND
BASAL PHOSPHORYLATION LEVELS
In mammalian cells, the Erk1/2-, p38-, and Jnk-MAPK
pathways are thought to be the three major signaling
cascades comprising the MAPK signaling system [34]. When
compared to lean animals, the diabetic plantaris and soleus
muscles exhibited increased amounts of Jnk-1 while in the
6 Experimental Diabetes Research
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Figure 3: Effects of concentric, maximal muscle contraction in
situ on phosphorylation of p38-MAPK. The basal (control) and
contraction-induced phosphorylation of the Jnk in plantaris and
soleus muscles from lean (LNZ) and obese Zucker (OSXZ) rats at
0, 1, and 3 hours after HFES. Phosphorylation of p38-MAPK was
determined by immunodetection of phosphorylation on Thr180
and Tyr182 (phospho-p38 α MAPK). An asterisk (∗) indicates
significant difference (P < .05) from the control time point within
animal model, and a cross (†) indicates significant difference (P <
.05) at corresponding time points across animal models.
diabetic soleus, the amount of Erk1/2 and phosphorylated
Erk1/2 was diminished (see Figures 1 and 2). Previous studies
examining Jnk levels in human skeletal muscle [35] and
Erk1/2 signaling in the obese Zucker gastrocnemius [36]
have yielded similar results. It is unclear why diabetes may
induce differences in the way different muscle types might
regulate the amount and basal activation of these proteins.
Indeed, previous studies investigating the effect of increased
glucose or the influence of diabetes on MAPK protein levels
and phosphorylation state have been equivocal. For example,
some studies have demonstrated no effect [37] while others
have suggested that altered glucose levels can increase [38]
or diminish the phoshorylation of these proteins [39].
The factor(s) responsible for differences between studies
are unknown but could be related to cell type-specific
responsesor to differences in the concentrations of glucose
tested or in the severity of hyperglycemia observed in
the experimental preparation. Similarly, diabetes-associated
changes in muscle fiber type may also be involved. For
example, Punkt and colleagues have recently demonstrated
that slow oxidative fiber fraction was reduced by 16% with
diabetes while the fast glycolytic fiber fraction was increased
by 49% in vastus lateralis of type II diabetic patients [40].
Given that the regulation of MAPK proteins may differ
between fiber types [41, 42], it is possible that fiber type
transitions associated with diabetes may be involved. Finally,
recent data has suggested that fast- and slow-twitch muscles
may rely on different signaling mechanisms to mediate
glucose uptake [43, 44]. Whether these differences explain
some or all of the alterations we observe in the present
investigation they will require further study.
6. EXERCISE-INDUCED SIGNAL TRANSDUCTION
IS ALTERED IN TYPE II DIABETIC MUSCLE
A major finding of this investigation is that the phosphoryla-
tion (activation) of MAPK proteins in response to a maximal
contractile stimulus appears to be altered in diabetic muscle.
In addition, our data suggest that diabetes may alter this
response differently in different muscle types. For example,
in the lean plantaris, Erk1/2 activation typically did not
reach maximal levels until three hours after cessation of
exercise. Conversely, in the obese plantaris, Erk1/2 activation
was maximal immediately following exercise and remained
high through three hours post exercise (see Figure 2).
Interestingly, this response appeared to be reversed in the
lean and obese solei (see Figure 2). Similar to what we
observed for the Erk1/2-MAPK proteins, the contraction-
induced phosphorylation of p38- and Jnk-MAPK appeared
to differ between the lean and obese animals. Unlike
the regulation of the Erk1/2-MAPK proteins, differences
between groups in the phosphorylation response of p38-
and Jnk-MAPK appeared to manifest themselves during
the later stages of the recovery period. For example, while
contraction failed to increase p38α phosphorylation in the
lean plantaris, p38α phosphorylation levels in the obese
plantaris muscles were dramatically increased at the three
hour post exercise time point (see Figure 3). Similarly, the
degree of Jnk phosphorylation was significantly elevated in
the obese, compared to lean plantaris muscles at the one hour
post exercise time point (see Figure 4). To our knowledge,
these findings have not been previously reported.
The time course and magnitude of increased MAPK
phosphorylation following muscle contraction we observe
in the lean animals are similar to that which have been
reported previously following various modes of exercise in
animal models as well as humans [45–51]. These responses
appear to be physiologically relevant, as they were associated
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Figure 4: Effects of concentric, maximal muscle contraction in situon phosphorylation of Jnk. The basal (control) and contraction-induced
phosphorylation of the Jnk1 (d),(e), Jnk2 (a),(b), Jnk3-MAPK (c) in plantaris and soleus muscles from lean and diabetic Zucker rats
at 0, 1, and 3 hours after contractile stimulus. Jnk phosphorylation was determined by Western analysis and immunodetection for Jnk
phosphorylation on Thr183 and Tyr185. An asterisk (∗) indicates significant difference (P < .05) from the control within animal model, and
a cross (†) indicates significant difference (P < .05) at corresponding time points across animal models.
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Figure 5: Contraction-induced p90RSK (MAPKAP-K1) and
MAPKAPK-2 phosphorylation are altered with type II diabetes.
Plantaris muscles from lean (LNZ) and obese Zucker (OSXZ) rats
were obtained immediately after, 1 and 3 hours after a bout of HFES.
Alterations in p90RSK (a) and MAPKAPK-2 (b) phosphorylation
with exercise were determined by immunoblotting. An asterisk (∗)
indicates significant difference (P < .05) from the control within
animal model, and a cross (†) indicates significant difference (P <
.05) at corresponding time points across animal models.
with the exercise-induced activation of p90RSK, a known
downstream target of Erk1/2 [21]. Similar to what was
observed with Erk1/2, the basal and contraction-induced
phosphorylation levels of p90RSK were significantly higher
in the obese, compared to lean plantaris at all time points.
How Erk1/2 and p90RSK may function in the diabetic
muscle or in producing exercise-induced muscle adaptation
is not well understood. The p90RSK has been proven to
be a ubiquitous and versatile mediator of Erk 1/2 signal
transduction with the activation of p90RSK being thought to
be involved in the regulation of nuclear factor-κB and in the
phosphorylation of transcription factors, including c-Fos,
Nur77, and cAMP response element-bindingprotein [52].
The physiological significance of the apparent enhancement
in Erk1/2 signaling we observe in diabetic muscle awaits
further clarification. Nonetheless, in the light of previous
data suggesting that MAPK and MAPK-associated signaling
may be important upstream regulators of load-induced
intracellular signaling events the results of the present
study are consistent with previous work suggesting that
diabetes may be associated by alterations in the ability of
skeletal muscle to adapt to an exercise stimulus [7, 9, 53–
56]. The extent to which the combined changes in tissue
content and action of the Erk 1/2 proteins may play a
role in the contracting diabetic muscle cannot be accurately
assessed without further studies designed to evaluate the
experimental manipulation of these proteins. Future studies
employing methods to directly test the effects of altered
Erk1/2 levels will with no doubt add to our understanding.
Why diabetes might be associated with differences in
the contraction-induced activation of MAPK proteins is not
readily apparent. It is thought that the MAPK proteins may
play a key role in regulating muscle glucose uptake, and
it has been hypothesized that the MAPK pathway may be
a potential target for therapeutic strategies to restore the
metabolic balance to type II diabetic patients. The differences
in MAPK activation between normal and diabetic muscles
we observed in the present study may be a compensatory
mechanism to bypass defects in insulin dependent signaling
[57]. Given the plethora of factors thought to be involved in
regulating MAPK activation (e.g., mechanical stretch, muscle
hypoxia, reactive oxygen levels, muscle damage, local release
of growth factors, and cytokines, etc.) it is possible that
the differences we observe between models could be due to
several factors [24]. Because we examined the regulation of
MAPK signaling following a series of in vivo contractions as
opposed to using an in vitro experimental preparation it is
unclear whether the alterations we found between models
are a by product of differences in systemic environment of
the exercising muscle or due to intrinsic alterations to the
muscles themselves. Further research, perhaps using other
experimental designs, will be with no doubt added to our
understanding.
In conclusion, the results of this study have shown that
contraction-induced regulation of MAPK signaling may be
altered in the skeletal muscles of the obese Zucker rat.
Because this model exhibits many of the same physiological
characteristics seen in type II diabetic humans, these data
suggest that diabetes may be associated with differences in
how skeletal muscle “sense” and “respond” to a contractile
stimulus. Whether similar findings would be observed in
other types of diabetes (e.g., type I) or in humans remains to
be determined. Given the potential of resistance training to
improve the diabetic condition and the importance of MAPK
signaling in regulating muscle adaptation, the findings of the
current study may help to reveal new approaches for treating
metabolic diseases and have applicability for the prescription
A. Katta et al. 9
of exercise programs aimed at improving muscle function in
diabetic individuals.
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